|
|
Article: ExonHit Will Participate in the MAPT Study for the Prevention of Cognitive Decline in Old People.(Clinical report)
- Article from:
- Business Wire
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
* A 3-year follow-up of cognitive functions in 1,200 aged and frail individuals
* Search of blood biomarkers associated with early cognitive decline
* First participation of ExonHit in an external prospective study
PARIS -- Regulatory News:
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of ...